What Aindo does

Aindo SpA is an Italian private company headquartered in Trieste that builds a synthetic data generation platform purpose-built for the European healthcare market. The platform transforms private, identifiable patient data into statistically robust synthetic cohorts and clinical language models that preserve clinical characteristics while removing identifiable information, enabling real-world evidence (RWE) generation, synthetic external control arms for clinical trials, health-system planning, and clinical intelligence for treatment comparison and medical reasoning. Underlying capabilities include generative AI for tabular, relational, and time-series healthcare data, specialized clinical NLP models trained on real and synthetic data, and privacy-preserving infrastructure designed to be GDPR-, AI Act-, and EHDS-ready, with certifications including Europrivacy Art 42 GDPR, ISO 9001, ISO 27001, and NIST Cybersecurity Framework alignment.

The company monetizes through enterprise B2B subscriptions (annual, quote-based) sold via a consultative field-sales motion to pharma and CROs (primary), healthcare providers and IRCCS research hospitals, and public administration/health authorities. Named customers span the Italian IRCCS hospital network, major pharma companies (Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Novartis), Italian universities, and regional health authorities (Regione FVG, ASUGI, Insiel, Area Science Park). GTM is supported by industry events, scientific content, and implementation partnerships with Deloitte, Engineering, and BIP. Aindo has raised approximately $11.8 million cumulatively across a 2019 European Data Incubator award, a 2021 seed led by Vertis, a 2023 round led by United Ventures, and a €2.1 million EIC Accelerator grant in February 2025; share capital is reported at €88,105.

Name

Aindo

Legal name

Aindo SpA

Website

https://aindo.ai

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Aindo is an Italian healthcare AI company that generates privacy-preserving synthetic patient data and clinical language models for pharmaceutical companies, IRCCS hospitals, and public health authorities across Europe.

Ownership category

akta.pro rank

Product category

Healthcare Synthetic Data Software

NAICS

Software Publishers (5132), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms (HLACAOAM)

akta.pro secondary industries

Real-World Data (RWD) Platforms & Clinical Data Curation (HLACAIAJ), De-identification, Tokenization & Privacy-Preserving Data Platforms (HLACAIAK), Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D) (HLAGAJAF)

Keywords

• Synthetic data generation
• Healthcare data analytics
• Clinical evidence platform
• Privacy preserving AI
• Real world evidence

Headquarters

HQ city

Trieste

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Synthetic Data Solutions: Aindo generates revenue through licensing synthetic data solutions to healthcare organizations, pharmaceutical companies, and research institutions. The platform enables evidence generation, real-world evidence, and external control arms for clinical research.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Aindo develops a synthetic data generation platform for the healthcare sector. It transforms private, sensitive patient data into privacy-preserving synthetic cohorts and clinical evidence, enabling real-world evidence (RWE) generation, external/synthetic control arms for clinical trials, public health planning, and clinical intelligence via specialized language models. The platform is purpose-built for European healthcare compliance (GDPR, AI Act, EHDS, ISO 27001, Europrivacy).

Product overview

Aindo offers a unified platform for synthetic data generation in healthcare, comprising four integrated solutions: Public Healthcare (for health system planning and forecasting), Real-world Evidence (for observational studies and RWE generation), External Control Arms (for clinical trial acceleration), and Clinical Intelligence (clinical language models for treatment comparison and medical reasoning). The platform transforms private healthcare data into certified, auditable synthetic data compliant with GDPR, AI Act, ISO 27001, and Europrivacy standards.

Differentiator

Problem solved

Functional benefit

Products and services

• Public Healthcare Enables health systems and healthcare organizations to plan, evaluate, and innovate securely by generating synthetic data that supports demand forecasting, scenario modeling, performance measurement, and evidence generation. Insights can be shared across organizations without exposing patient-level data. Designed for hospitals, regional health authorities, and public administration.
• Real-world Evidence Provides researchers and life sciences teams with faster access to real-world data through high-quality synthetic cohorts that reflect real patient populations. Accelerates observational studies, outcomes research, and Real World Evidence generation while meeting regulatory requirements. Targets researchers, clinicians, and life sciences teams.
• External Control Arms Accelerates clinical trials by providing validated synthetic control arms that complement or replace traditional control groups with statistically robust foundations. Reduces recruitment needs, costs, and operational complexity, making studies faster and more efficient. Designed for pharmaceutical companies and CROs.
• Clinical Intelligence Supports faster and better-informed clinical decisions through specialized clinical language models that assist treatment comparison, medical reasoning, and knowledge access. Trained on real and synthetic data for high-complexity healthcare environments. Built for clinicians and clinical researchers.

Quantifiable outcome

• Access time reduced from months to instant
• +2 more outcomes

Named customers22 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature4 records

Partnerships

Nine partnerships are on record, tiered minor, core and moderate.

• dhcminorStrategic or Co-development PartnerDigital Health Accelerator program organized by dhc and Tenity selected 8 startups including Aindo for its third cohort running until October 2025. Program provides mentorship, industry leader access, and investor networks.
• TenityminorStrategic or Co-development PartnerDigital Health Accelerator program organized by dhc and Tenity. Provides participants access to mentorship, industry leaders, and investor networks including founding partner Zürcher Kantonalbank.
• AICROpluscoreStrategic or Co-development PartnerAindo announced membership in AICROplus to integrate Artificial Intelligence and synthetic data into clinical research, accelerating healthcare innovation. AICROplus is an Italian association for clinical research organizations.
• Green Future ProjectminorOthersCollaboration with Green Future Project and BizAway to support the Rimba Raya Biodiversity Reserve in Indonesia as part of Aindo's sustainability initiatives.
• BizAwayminorOthersTravel management company collaborating with Aindo on sustainability projects through support of the Rimba Raya Biodiversity Reserve in Indonesia.
• DeloittemoderateImplementation/ SI/ Consulting PartnerProfessional services firm providing consulting and implementation support. Deloitte is listed among Aindo's partner ecosystem for healthcare data solutions.
• EngineeringmoderateImplementation/ SI/ Consulting PartnerItalian technology and consulting company listed as a partner for healthcare data and digital transformation initiatives.
• BIPminorImplementation/ SI/ Consulting PartnerBusiness integration partner providing consulting services in the healthcare and technology space.
• CVBFminorStrategic or Co-development PartnerConsorzio Veneto about Biomedical Research focused on clinical and biomedical research collaborations.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• MDClone: Israel-based company offering synthetic health data generation and analytics for hospitals and life sciences. Directly comparable to Aindo's RWD/RWE and public healthcare offerings, with similar privacy-preserving approach and healthcare-institution go-to-market.
• Syntegra: US-based startup focused on synthetic healthcare data for RWE generation and clinical research. Competes head-to-head with Aindo on synthetic cohorts, RWE, and external control arms for pharma clients.
• TripleBlind: Privacy-preserving data collaboration platform serving healthcare and life sciences. Directly competes with Aindo's privacy-preserving AI infrastructure for clinical research, RWE, and healthcare data collaboration use cases.
• Gretel.ai: Synthetic data platform for developers and enterprises across healthcare and other verticals. Comparable core technology (synthetic data generation), with Aindo differentiating via healthcare specialization and European regulatory certifications.
• Mostly AI: Austrian synthetic data platform serving financial services, healthcare, and public sector. Closely comparable technology and European regulatory positioning, making it a near-direct competitor for European healthcare and public-sector buyers.

Emerging players

• Owkin: Federated learning and AI platform for healthcare and life sciences, with similar European regulatory positioning and pharma/biopharma customer base. Overlaps with Aindo on privacy-preserving clinical research, though focused on federated learning rather than synthetic data.
• DataCebo: Commercial entity behind the Synthetic Data Vault (SDV), offering enterprise synthetic data tooling. Comparable synthetic data technology stack, with Aindo differentiating via healthcare verticalization and certified European regulatory compliance.

Broad incumbents

• Flatiron Health: Roche-owned RWE platform for oncology, with deep EHR-derived datasets and pharma analytics. Competes with Aindo in the pharma RWE and external control arm categories at much larger scale.
• IQVIA: Global clinical research services and RWE giant with extensive data assets and pharma relationships. A broad incumbent whose RWE, real-world data, and clinical trial services overlap with Aindo's offerings to pharma customers.
• Tempus Labs: US healthcare AI and data platform with large molecular and clinical datasets serving pharma R&D. Competes with Aindo on RWE, biomarker discovery, and AI-augmented clinical research, though at vastly larger scale and US-centric footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aindo